<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Arena Pharmaceuticals Inc. | Company News & Executive Profiles - ARNA | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/arena+pharmaceuticals+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Arena Pharmaceuticals Inc.]]></description>
	<s:counts start="0" returned="10" found="26" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-363502.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions Your first question comes from Craig Gordon - Cohen & Co. Craig Gordon - Cohen & Co. A couple questions, in the NDA Submission, do you guys plan on submitting proposals both for Phase IV commitments as well as a REMS program? Bill Shanahan We...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 10 Nov 2009 11:07:09 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/capital+market.html"><![CDATA[Capital Market]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/partnership.html"><![CDATA[Partnership]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force.html"><![CDATA[Sales Force]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/contingency+plan.html"><![CDATA[Contingency Plan]]></category>
		<category domain="http://resources.bnet.com/topic/arena+pharmaceuticals+inc..html"><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/business+structures.html"><![CDATA[Business Structures]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/financial+services.html"><![CDATA[Financial Services]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARNA</category>
		<category domain="tickers">ARNA</category>
	</item>
	<item>
		<title><![CDATA[Arena?s Lorcaserin Has Safety Edge]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F162550-arenas-lorcaserin-has-safety-edge%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Results from Arena&#8217;s ARNA phase III BLOSSOM study are strikingly similar to the BLOOM study, with mean total weight loss for the 10mg lorcaserin BID group coming in at 17.0 lbs in BLOSSOM vs. 17.9 lbs in BLOOM. These equated to 7.9% and 8.2% mean absolute...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 21 Sep 2009 07:41:57 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/arena+pharmaceuticals+inc..html"><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARNA</category>
		<category domain="tickers">ARNA</category>
	</item>
	<item>
		<title><![CDATA[Two Positive Notes for Arena Pharmaceuticals]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F162198-two-positive-notes-for-arena-pharmaceuticals%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ruthanne Williams Roussel submits: Arena ARNA releases more top-line pivotal data on flagship obesity drug lorcaserin, this time from its BLOSSOM study Behavioral modification and Lorcaserin Second Study for Obesity Management Friday 9/18, before market open. Two things that could be great for ARNA: by Ruthanne Williams Roussel]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 18 Sep 2009 02:06:38 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/ruthanne+williams+roussel.html"><![CDATA[Ruthanne Williams Roussel]]></category>
		<category domain="http://resources.bnet.com/topic/arena+pharmaceuticals+inc..html"><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARNA</category>
		<category domain="tickers">ARNA</category>
	</item>
	<item>
		<title><![CDATA[Arena: Obesity Is a Large Market Opportunity]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F153833-arena-obesity-is-a-large-market-opportunity%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Large Market Opportunity... In our view, obesity remains the single largest opportunity for a new pharmaceutical product today. Roughly two-thirds of the U.S. population is overweight. The number is expected to grow to 75% by 2015. There is massive unmet medical need and clear pharmacoeconomic benefits...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 05 Aug 2009 01:25:31 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/arena+pharmaceuticals+inc..html"><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARNA</category>
		<category domain="tickers">ARNA</category>
	</item>
	<item>
		<title><![CDATA[Arena Patients Keep Weight Off, Bodes Well for Partnership]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F142362-arena-patients-keep-weight-off-bodes-well-for-partnership%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ruthanne Williams Roussel submits: Arena's big news at the American Diabetes Association meeting last weekend was that the analysis of the two-year pivotal Phase III BLOOM study data showed that patients were keeping off the weight they were losing on lorcaserin.   This of course is terrific and bodes...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 10 Jun 2009 03:19:32 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/ruthanne+williams+roussel.html"><![CDATA[Ruthanne Williams Roussel]]></category>
		<category domain="http://resources.bnet.com/topic/arena+pharmaceuticals+inc..html"><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARNA</category>
		<category domain="tickers">ARNA</category>
	</item>
	<item>
		<title><![CDATA[Arena's Prospects Will Be in the Eye of the Suitors]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F139304-arena-s-prospects-will-be-in-the-eye-of-the-suitors%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  I&#8217;ve been getting a lot of objections to my opinion on Arena&#8217;s ARNA obesity candidate lorcaserin. Specifically, the first level of the dispute seems to be whether or not the recent clinical trial results met the FDA&#8217;s criteria for efficacy or not. So, let&#8217;s look at...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Sun, 24 May 2009 12:10:57 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/arena+pharmaceuticals+inc..html"><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARNA</category>
		<category domain="tickers">ARNA</category>
	</item>
	<item>
		<title><![CDATA[Arena Pharma Could Be on the Verge of Collapse]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F138293-arena-pharma-could-be-on-the-verge-of-collapse%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  I wrote in March about locaserin, Arena Pharmaceutical's ARNA serotonin ligand for obesity. Their clinical data had come out, and things at least to me didn't look good. They didn't quite make the minimum threshold for efficacy, and the FDA isn't in a mood to take...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 18 May 2009 12:38:43 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/arena+pharmaceuticals+inc..html"><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARNA</category>
		<category domain="tickers">ARNA</category>
	</item>
	<item>
		<title><![CDATA[Arena's Obesity Drug Not Likely to Make It]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F128717-arena-s-obesity-drug-not-likely-to-make-it%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Derek Lowe submits:  One of the drug targets for obesity that&#8217;s been kicking around for years now is a serotonin-receptor based idea, a 5-HT2c agonist. There are several lines of evidence that make this a plausible way to affect appetite &#8211; well, as plausible as any of the appetite-based...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 31 Mar 2009 07:47:24 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/derek+lowe.html"><![CDATA[Derek Lowe]]></category>
		<category domain="http://resources.bnet.com/topic/arena+pharmaceuticals+inc..html"><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARNA</category>
		<category domain="tickers">ARNA</category>
	</item>
	<item>
		<title><![CDATA[Arena's Financing Deal with Azimuth Is a Healthy Move]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F127704-arena-s-financing-deal-with-azimuth-is-a-healthy-move%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mark Cifra submits: Secondaries and convertibles are pretty common stuff to most biotech investors. That is why when I first read the news that Arena Pharmaceuticals ARNA signed an equity financing commitment deal for 50 million dollars, I figured it was the same old biotech secondary. Until I caught the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 25 Mar 2009 01:15:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mark+cifra.html"><![CDATA[Mark Cifra]]></category>
		<category domain="http://resources.bnet.com/topic/arena+pharmaceuticals+inc..html"><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARNA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="tickers">ARNA,ONXX</category>
	</item>
	<item>
		<title><![CDATA[Arena Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-278236.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Operator Instructions.   Our first question will come from Alan Carr with Needham. Alan Carr &#8211; Needham  Could you clarify a bit your financial guidance for &#8217;08?  You said that your expenses for this year, you ended with 110, but I was wondering...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 12 Mar 2009 20:19:15 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/needham+%2526+co..html"><![CDATA[Needham & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/arena+pharmaceuticals+inc..html"><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/business+structures.html"><![CDATA[Business Structures]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARNA</category>
		<category domain="tickers">ARNA</category>
	</item>
</channel>
</rss>
